Thea Pharma received FDA approval

Thea Pharma, the US subsidiary of France’s Laboratoires Théa, has received FDA approval for a preservative-free version of latanoprost formulations used to lower elevated intraocular pressure in the eyes.

Many companies currently sell latanoprost eye drops in the US but the existing options contain preservatives such as benzalkonium chloride that studies have shown to be potentially damaging to the eye surface.

The formulation that was approved has been sold in Europe as Monoprost since 2013.

Click here to read the entire article.